Quest Diagnostics study finds 29.5% of Lyme-seropositive patients show antibodies to other tick-borne pathogens

By Public Technologies
  • Quest Diagnostics highlighted a clinical study published in JAMA Network Open on tick-borne co-exposure in suspected Lyme patients.
  • Results have already been published, based on de-identified US test results collected from January 2021 through December 2025.
  • Study found many patients with Lyme exposure also showed evidence of exposure to other tick-borne pathogens, raising missed-diagnosis risk.
  • Findings support broader, multi-pathogen testing to guide treatment choices, since some co-infections require different management than Lyme disease.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quest Diagnostics Incorporated published the original content used to generate this news brief via PR Newswire (Ref. ID: NY51726) on September 21, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.